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Open access under CC BY-NC-ND license.The persistence and spread of antibiotic resistance, in
conjunction with decreased profitability of new antibio-
tics, have created the dangerous prospect of ineffective
therapies against bacterial diseases. National strategies
aimed at discovery, development, and definition of the
mechanisms of effective antibiotic alternatives, especial-
ly for agricultural applications, should be encouraged.
The time has come for innovative and bold solutions to
slow resistance to antibiotics and speed the development of
new antibacterials [1]. Unlike the so-called golden age
of antibiotics, when many antibiotic classes were discov-
ered and commercialized, the discovery and release of
new antibiotics have dramatically decreased in the past
decades. For instance, there have been no new classes of
antibiotics to treat Gram-negative bacteria, such as
Escherichia coli and Salmonella enterica, in over 40 years
[1]. At the same time, extensively drug-resistant and pan-
resistant (resistant to all therapeutic antibiotics) strains of
these bacteria have been identified in human and veteri-
nary clinics.
Since the 1990s, both the decline in attractiveness of the
antibiotic market and consolidations within the biophar-
maceutical industry have resulted in a 75% decrease in the
number of companies with large antibiotic R&D efforts
[2,3]. In 2004, antibiotics represented fewer than 2% of
drugs in clinical development by the 15 largest drug com-
panies [4].
The pursuit of new antibiotics has decreased because of
a decrease in profitability from the effort. As pointed out by
Sharma and Towse [5], antibacterials are not an attractive
option for investors seeking quick and substantial returns
on their investments. The development of an antibiotic
drug from discovery through approval is estimated to cost
between $0.8 and $1.7 billion. Finding or creating new
antibiotics in the laboratory has become more challenging
[6]. Easily discovered antibiotic classes have already been
found, often serendipitously and through traditional em-
pirical assays of fermentation products. Current discovery
approaches require specialized technologies and are aimed
at specific molecular targets [1,5,6]. They have yielded
chemical compounds that kill bacteria but lack the desir-
able biological and economic properties of the golden-age
antibiotics, such as broad activity spectra [6]. In addition,
government safeguards and regulatory requirements, es-
pecially for the approval of non-traditional antibiotics,
prolong market release and add to development costs [1,3].DOI of original article: http://dx.doi.org/10.1016/j.tim.2012.11.001.
Corresponding author: Stanton, T.B. (thad.stanton@ars.usda.gov).
Keywords: antibiotic; agriculture; resistance; probiotics; prebiotics; bacteriophage.With rare exception, antibiotic therapy for humans is for
short-term use. There is more profit and thus more incentive
for companies to invest in drugs for frequent, long-term use,
such as cancer, cardiovascular, psychoneurological, and
lifestyle-targeted therapies. Despite legislative efforts to
extend patent protection times for new antibiotics, they
are insufficiently attractive as commercial products to be
developed without guaranteed sales. In the absence of wide-
spread life-threatening bacterial diseases, antibiotic pro-
ducts are currently not profitable and returns on R&D
investments can no longer be assured.
Paradoxically, because the pursuit of new antibiotics
has decreased there is an increasing need for the discovery
of antibiotics to combat antibiotic-resistant bacteria. As
discussed by Andersson and Hughes [7], it is very likely
that the antibiotic resistance problem resulting from the
extensive use and misuse of antibiotics for human, animal,
and plant purposes will continue, at least for the foresee-
able future.
At one time, antibiotic resistance was considered to be a
biologically costly trait. In the absence of antibiotic selec-
tion, gene mutations or extra genes conferring resistance
were predicted to be handicaps for resistant bacteria in
competition with sensitive bacteria and were thus thought
of as dispensable. Now, however, experimental data from
both clinical and research laboratories have led to the
conclusion that antibiotic resistance genes exist and sta-
bly persist in bacteria with or without antibiotic selection
[7–9].
Host-associated microbial ecosystems are common sites
where antibiotic resistance persists. One of the most di-
versely populated bacterial ecosystems is the animal (hu-
man) intestinal tract. The intestinal ecosystem contains
approximately 100 trillion non-pathogenic bacteria repre-
senting upwards of 500–1000 different bacterial species.
These microbes make essential contributions to the health
and wellbeing of their host animal. They are also a reser-
voir for antibiotic resistance genes. A significant, and
usually large, proportion of the bacterial species in that
ecosystem is resistant to one or more antibiotics despite the
fact that the individual animal (and its intestinal microbial
denizens) has never been exposed to an antibiotic. In one
study of antibiotic-free swine from organic farms, over 70%
of E. coli and 16% of the total anaerobic bacteria popula-
tions were chlortetracycline-resistant [10]. Several expla-
nations for the persistence of antibiotic resistance have
been proposed or demonstrated (Box 1). By inference,
antibiotic resistance will continue to exist at some level
in microbial populations even with restrictions on antibi-
otic use. Antibiotic use selects for an increase in existing
resistant bacteria, encourages the spread of resistance111
Box 1. Explanations for the persistence of antibiotic
resistance*
 Genetic-free trade agreements: genes for antibiotic resistance
flow freely and widely across bacterial groups within an
ecosystem such as the intestinal tract. Non-pathogenic bacteria
serve as reservoirs of antibiotic resistance for other non-patho-
gens and for pathogens.
 Multiple use: antibiotic resistance mechanisms have other uses in
bacteria, for example, potassium transport or protection from
intestinal bile acids.
 Co-selection of gene clusters: genes for resistance to one antibiotic
physically link (on transferable genetic elements such as plasmids,
transposons, integrons, and bacterial viruses) to other genes
conferring fitness on bacteria or on the genetic element. Examples
include resistance to mercury and resistance to copper. The
benefits of a single gene can promote the survival of multiple
genes when the genes are shared as a unit between bacteria.
 Constant exposure: antimicrobial resistance genes are continually
recycled from the environment, carried via bacteria in food, water,
air, soil, and animal-to-animal contact. Tetracycline resistance
genes, for example, have been detected in feed and antibiotics
given to animals. Resistance genes exist naturally in pristine soil
and water environments [14].
 Compensation mechanisms: gene mutations resulting in anti-
biotic resistance are offset by other gene mutations or by
duplication of genes and antibiotic resistance genes are switched
off. As a result, the competitive fitness of the bacterium is not
weakened when antibiotics are absent.
 Sub-MIC selection: ultra-low concentrations of antibiotics (con-
taminating residues or levels found in natural environments, such
as soil) do not kill susceptible bacteria but reduce their growth
rates, so resistant bacteria outgrow them.
 Subspecies diversity in complex ecosystems.
*Based on Stanton and Humphrey (http://www.feedinfo.com/
console/PageViewer.aspx?page=185602) and Andersson and
Hughes [7].
Box 2. A USDA invention to reduce animal-to-human
transmission of antibiotic-resistant bacteria
In 2000, two ARS scientists, Tom Casey and Mark Rasmussen, and
an Iowa State University colleague, Jacob Petrich, received a
Superior Service Honor Award from the US Secretary of Agriculture
and a National R&D 100 award for the invention of a fluorescence
detector. The detector monitors, in real time, fecal contamination of
animal carcasses in meat processing plants. Fecal contamination is
a significant source of foodborne pathogens and spoilage bacteria
in meat products [15].
This invention will reduce the transmission from meat to humans
of antibiotic-resistant foodborne pathogens and non-pathogens.
Ideally, the invention will be widely adopted if not mandated.
Any method that prevents the spread of fecally transmitted
bacteria will curb the spread of antibiotic resistance genes. It will
also reduce antibiotic use in farm animals and in humans, for
example, by reducing the number of foodborne illnesses that must
be treated with antibiotics.
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communities, and drives the evolution of resistance mech-
anisms.
A reliable supply of effective antibacterials for food
animals and humans is essential to the health and wellbe-
ing of the citizens of a nation, as are a secure supply of
wholesome food and a strong agricultural economy. Anti-
biotics in the USA are used for growth promotion and to
prevent or treat diseases of livestock. Several hypotheses
surround the growth promotion effects of antibiotics, in-
cluding prevention of low-grade bacterial infections [11].
Antibiotic treatment of low-grade infections and antibiotic
use to prevent animal disease induced by management
stress, such as transport, have been considered prophylac-
tic therapies. Annually, an estimated 1000 tons of macro-
lide and tetracycline antibiotics (alone) are added to swine
diets for these purposes [12].
There is major debate over the effects of agricultural
antibiotic use on human health. There is concern that the
use of antibiotics in food animals can lead to dissemination
of antibiotic resistance genes from animals to humans,
especially through or to human bacterial pathogens.
Movement of bacteria occurs regularly, back and forth,
between animal farms and human communities through
air, water, direct physical contact, and, notably, via the
food chain. In view of the animal origin of foodborne
pathogens, such as E. coli O157:H7, Salmonella enterica
serovar Typhimurium, and Campylobacter species, it is112implausible that antibiotic use in animals does not select
for antibiotic-resistant bacteria that can pass to humans
through animal products. Detection of fecal contamination
of meat products could be one mechanism to prevent
dissemination of resistant bacteria through the food chain
and to reduce antibiotic use (Box 2).
Meat is a significant, often preferred, protein source in
human diets. Large-scale efficient production of meat ani-
mals in the USA is an essential contributor to food biose-
curity. Important unanswered questions surround the
impact of antibiotic limitations on agricultural productivi-
ty. To what degree will restrictions on agricultural use
reduce the incidence of human antibiotic resistant infec-
tions, given widespread antibiotic use in humans and the
persistence of antibiotic resistance? To what degree will
restrictions impact human health by reducing the afford-
ability of an important protein source?
The continuous and substantial use of antibiotics for
agriculture is prudent for those who have the goal of
maintaining a healthy agricultural economy. Ironically,
long-term substantial antibiotic use in agriculture leads
to more difficult-to-treat animal diseases caused by multi-
ply and highly resistant bacteria [13]. The continuous and
large-scale use of antibiotics for agriculture is imprudent
for those who support efficacious antibiotics for human
health. Ironically, antibiotic use in agriculture ensures the
profitability that supports R&D budgets for biopharma-
ceutical companies to discover new antibiotics. Both sides
hold arguable, but incompatible, positions. An inability to
find common ground has led to decades of debate and either
legislation or no legislation, based on the political influence
of either side. In the meantime, antibiotic resistance and
the lack of new antibacterials loom as problems for both
agriculture and human health.
It is time for a new prescription for antibacterials, one
involving antibiotic alternatives. To sustain a healthy
agricultural economy and preserve antibiotics for humans,
we can no longer ignore any strategy to reduce antibiotic
use and prevent the spread of antibiotic resistance (Box 2).
The decades-long debates and impasse over agricultural
antibiotic use and human health need to give way to a
common-ground concurrence to evaluate existing products
and discover or develop new products that are alternatives
to traditional antibiotics for animal health [11].
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discovery efforts of research laboratories are aimed at
these products through the support of private venture
capital. From a discovery perspective, these private labo-
ratories should also recognize the potential profit and
societal benefits of antibiotic alternatives for enhancing
livestock performance and health, in other words, products
fed daily to large numbers of animals over long periods of
time. Furthermore, from a development perspective, anti-
biotic alternatives for livestock health, unlike products for
humans, can be tested early and directly in the target
animal species.
It is also time for government and public institutes to
become more involved in the discovery of antibiotic alter-
natives. There is a need for nationally coordinated, interdis-
ciplinary, multi-agency (human and animal health) efforts
to encourage research on promising antibiotic alternatives.
All physical, chemical, immunological, genetic, and biologi-
cal approaches should be considered, with fast tracking of
the most promising. Cooperative research should be encour-
aged between public institutes and private corporations to
confirm, define, and improve the efficacy of existing non-
antibiotic health products for animals.
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